TORONTO, April 13, 2022 /CNW/ - Canntab Therapeutics Limited (CNSX:PILL.CN) (OTC-BB:CTABF) (FRA:TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that the Company has engaged Mr. Hamish Sutherland as a strategic business consultant to work with Canntab and develop additional sales and distribution channels for the extensive suite of Canntab's products and to assist Canntab in reaching strategic partnerships in the Cannabis industry with a view to enhancing shareholder value.
Read more at newswire.caCanntab Engages Hamish Sutherland as Strategic Advisor
Newswire.ca - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here